BiosimilarBiological
GP2013 clinical trials
Also written GP2013.
A product of Rituximab; its studies count on that page too.
- studies test it
- 4
- open now
- 0
- in phase 3
- 2
- first study started
- 2011
How studies write it
Studies that test it under each name
Development codes
Studies by the year they started
4 studies that test it; most in 2011 (2)
| Year | Studies |
|---|---|
| 2011 | 2 |
| 2013 | 1 |
| 2015 | 1 |
By phase
A phase 1/2 study counts in both.
- Phase 1
- 2
- Phase 2
- 1
- Phase 3
- 2
What it is tested for
Each study’s main condition, where its own words name it.
Who runs them
Industry 4 · Other 0
Studies
Open first, then newest update. How each study uses GP2013 is read from its arms, and is right about nine times in ten.
Testing it · 4
- GP2013 in the Treatment of Patients With Previously Untreated, Advanced Stage Follicular Lymphoma (ASSIST_FL)CompletedPhase 3SandozNCT01419665Written as GP2013
- GP2013 in Japanese Patients With CD20 Positive Low Tumor Burden Indolent B-cell Non-Hodgkin's LymphomaCompletedPhase 1SandozNCT01933516Written as GP2013
- GP2013 in the Treatment of RA Patients Refractory to or Intolerant of Standard TherapyCompletedPhase 1/2SandozNCT01274182Written as GP2013
- GP2013 Treatment in Patients With Active Rheumatoid Arthritis, Previously Treated With Rituxan® or MabThera®CompletedPhase 3SandozNCT02514772Written as GP2013 - A Proposed biosimilar rituximab